Astria Therapeutics, Inc. (ATXS) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.21
↑+127% vs avg
5yr avg: 0.97
30Y Low0.4·High2.7
ROE
↑
-33.5%
↓+61% vs avg
5yr avg: -86.4%
30Y Low-365%·High-30%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ATXS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Astria Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $718M | $502M | $231M | $218M | $48M | $39M | $66M | $22M | $32M | $59M | $64M |
| Enterprise Value | $664M | $448M | $56M | $198M | $-38036318 | $15M | $59M | $7M | $18M | $41M | $10M |
| P/E Ratio → | -7.49 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | 64.61 | — | — |
| P/B Ratio | 2.21 | 1.57 | 0.95 | 0.98 | 0.39 | 0.97 | 1.85 | 0.63 | 2.74 | 2.01 | 1.26 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ATXS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | 36.83 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ATXS Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -33.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 100.0% | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | -5418.8% | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | -5472.8% | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -33.5% | -33.5% | -31.4% | -30.2% | -239.2% | -97.7% | -74.4% | -110.7% | -133.9% | -90.6% | -64.6% |
| ROA | -31.6% | -31.6% | -30.0% | -28.9% | -222.8% | -83.6% | -65.0% | -90.7% | -94.2% | -69.1% | -81.4% |
| ROIC | -50.3% | -50.3% | -46.2% | -33.7% | -552.3% | -125.2% | -85.1% | -225.4% | -445.9% | -677.6% | — |
| ROCE | -39.4% | -39.4% | -35.7% | -31.1% | -238.7% | -96.2% | -75.5% | -112.5% | -123.8% | -80.5% | -92.9% |
ATXS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $60M exceeds total debt of $5M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.03 | 0.06 | — | 0.21 | 0.20 | 0.18 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.17 | -0.72 | -0.09 | -0.70 | -0.59 | -0.21 | -0.44 | -1.18 | -0.61 | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -263.71 | -58.65 | -42.48 | -32.37 |
Net cash position: cash ($60M) exceeds total debt ($5M)
ATXS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Astria Therapeutics, Inc.'s current ratio of 17.49x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 25.13x to 17.49x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.49 | 17.49 | 21.73 | 25.13 | 24.42 | 7.25 | 7.74 | 9.33 | 2.90 | 4.75 | 8.14 |
| Quick Ratio | 17.49 | 17.49 | 21.73 | 25.13 | 24.42 | 7.25 | 7.74 | 9.33 | 2.90 | 4.75 | 8.14 |
| Cash Ratio | 17.15 | 17.15 | 21.34 | 24.99 | 24.12 | 7.03 | 7.20 | 9.01 | 2.72 | 4.63 | 8.04 |
| Asset Turnover | — | — | — | — | — | — | — | — | 0.03 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
ATXS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Astria Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $56M | $30M | $15M | $9M | $3M | $2M | $842472 | $361359 | $270503 | $134032 |
Peer Comparison
Compare ATXS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ATXSYou | $718M | -7.5 | — | — | — | — | -33.5% | -50.3% | — |
 KALV | $1B | -7.2 | — | — | — | — | -121.5% | -152.3% | — |
 BCAB | $5M | -0.1 | — | — | 100.0% | -2965.3% | — | — | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 ARDX | $2B | -26.8 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 CGEM | $905M | -4.0 | — | — | — | — | -44.0% | -43.5% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 XOMA | $490M | 28.3 | 37.5 | 170.6 | 94.3% | 21.8% | 38.2% | 7.4% | 9.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See ATXS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATXS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATXS vs KALV
Side-by-side business, growth, and profitability comparison vs KalVista Pharmaceuticals, Inc..
Start ComparisonATXS — Frequently Asked Questions
Quick answers to the most common questions about buying ATXS stock.
What is Astria Therapeutics, Inc.'s P/E ratio?
Astria Therapeutics, Inc.'s current P/E ratio is -7.5x. This places it at the 50th percentile of its historical range.
What is Astria Therapeutics, Inc.'s ROE?
Astria Therapeutics, Inc.'s return on equity (ROE) is -33.5%. The historical average is -115.6%.
Is ATXS stock overvalued?
Based on historical data, Astria Therapeutics, Inc. is trading at a P/E of -7.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.